Editas Medicine Announces Appointment of James C. Mullen as Chief Executive Officer Cindy Collins to Step Down Effective February 15, 2021
February 08, 2021 08:00 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES
CAMBRIDGE, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that James (Jim) C. Mullen will succeed Cynthia (Cindy) Collins as Chief Executive Officer, effective February 15, 2021. Mr. Mullen will continue as Chairman of the Company’s Board of Directors.
“On behalf of the entire Board, I thank Cindy for her tremendous contributions and dedication to Editas Medicine,” said James C. Mullen, Chairman, Editas Medicine. “Under Cindy’s leadership, the Company initiated the EDIT-101 clinical trial – the first ever administration of an